BridgeBio 承諾向 Speak Foundation LGMD 卓越中心提供 30 萬美元

BridgeBio 與 Speak Foundation 合作，資助擴大由患者主導的 LGMD 卓越中心。此計畫旨在改善肢帶型肌肉萎縮症患者的專科照護協調、研究準備度，以及取得新興治療的機會。BridgeBio 正在開發 BBP-418 (ribitol) 用於 LGMDR9。

關鍵事實

申報時間: 2026年10月1日下午09:00
事件: 合作 / 授權交易
方向: 中性
公司: BBIOBridgeBio
資產: acoramidis
來源: 公司新聞稿
可信度: 有出處
承諾: 兩年內 30 萬美元

來源摘錄

The Speak Foundation Announces $300,000 BridgeBio Commitment to Advance Patient-Led LGMD Centers of Excellence The Speak Foundation Announces $300,000 BridgeBio Commitment to Advance Patient-Led LGMD Centers of Excellence News provided by The Speak Foundation Oct 01, 2026, 09:00 ET Share this article Share to X Share this article Share to X WASHINGTON , Oct. 1, 2026 /PRNewswire/ -- The Speak Foundation is pleased to announce a $300,000 commitment over two years from BridgeBio Pharma, Inc. to support and expand its national LGMD Centers of Excellence program, a patient-led initiative designed to strengthen specialized care, research readiness and access to emerging treatments for people living with limb-girdle muscular dystrophy. The patient-designed Centers of Excellence are inte

公司新聞稿